In liver cancers, Deferoxamine (DFO) can upregulate the expression of the IFN-γR2 chain, alleviating the IFN-γ resistance caused by the imbalance in the expression of IFN-γR1 and IFN-γR2 chains and promoting the apoptosis of tumor cells (152). Here, IFNG is linked to liver cancer.